Key result
Fasudil treatment in dysferlin-deficient SJL/J mice exacerbated the muscle disease phenotype, significantly reducing horizontal activity and soleus muscle force compared to untreated controls.
Population
60 male mice (30 dysferlin-deficient SJL/J and 30 C57BL/6 controls), 6 weeks old, weighing 20-25 g.
Comparison
Fasudil 75 mg/kg body weight via drinking water… vs Untreated controls receiving normal water.
Design
Preclinical, Each strain of mice was randomly separated into 2 groups…
Follow-up
16 weeks
Authors
Loading...
Fasudil exacerbates disease in dysferlin-deficient mice; leaves open rho-kinase inhibition utility in human dysferlinopathy.
Absolute Event Rate: 306.5% vs 405.5%
p-value: p=0.0138
In a preclinical model of dysferlin-deficient myopathy, treatment with the rho-kinase inhibitor fasudil exacerbated the muscle disease phenotype despite reducing macrophage infiltration.
Rayavarapu et al. (2010) studied Dysferlin deficient myopathy (n=60). Fasudil vs. Untreated (normal water) was evaluated on Horizontal activity at 25 weeks (p=0.0138). Fasudil treatment in dysferlin-deficient SJL/J mice exacerbated the muscle disease phenotype, significantly reducing horizontal activity and soleus muscle force compared to untreated controls.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: